• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • Procedures for initiating verification and testing of drug registration (Trial) in 2022

Procedures for initiating verification and testing of drug registration (Trial) in 2022

Acceptance and Examination of Chemical APIs
Tuesday, 25 January 2022 / Published in News, NMPA Registration in China, Pharmaceuticals & DMF

Procedures for initiating verification and testing of drug registration (Trial) in 2022

On December 20, 2022, the CDE (Center for Drug Evaluation) published (No.54-2021) the trial working procedures for initiating drug verification and testing with immediate effect from January 1, 2022, onwards. The trial working procedures is a supplementary regulation to the SAMR (State Administration for Market Regulation) Order No.27 on Administrative Measures for Drug Registration.

According to the trial regulation, the CDE will determine whether on-site verification needs to be initiated based on the risk factors of the drug itself and compliance factors of R&D and production entities.

Highlights

  • For drug registration applications that require the initiation of drug verification, the CDE shall notify the CFDI (Center for Food and Drug Inspection) to start the verification process within 40 working days after the application for drug registration is accepted, and the CDE will hand over the verification tasks and the related materials to the CFDI.  In principle, the on-site verification should be completed in 40 working days before the end of the review period. The results will be provided back to the CDE for review and submitted along with the dossier for drug registration.
  • Chapter 5 of this working procedure specifies the drug registration applications that require drug testing, which is consistent with the original relevant regulations and will not be repeated here.
  • For drug registration applications, the time limitation for drug testing from start to finish is the same for drug verification.

By Yu Fang and Jacky Li. Contact Cisema if you would like to learn more.

Tagged under: Drug Testing, Drug verification, drugs

What you can read next

NMPA Finally Updates IVD Reagent Classification
China Medical Device Standards
December 2021 Regulatory Roundup for Medical Device Mandatory Standards
Cross Border E-Commerce (CBEC): 24 New Zones and New List of Retail Imported Commodities

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Clinical trials of sodium hyaluronate complex solution

    Clinical trials of sodium hyaluronate complex solution – draft guidelines issued

    Clinical trials of sodium hyaluronate complex s...
  • China registration of ophthalmic optical measurement devices

    China registration of ophthalmic optical measurement devices – Technical review guidelines issued

    China registration of ophthalmic optical measur...
  • Pre-communication for Hainan medical device clinical RWD

    Pre-communication for Hainan medical device clinical RWD application – Trial measures implemented

    Pre-communication for Hainan medical device cli...
  • Registration platform for cosmetic raw materials safety information

    Registration platform for cosmetic raw materials safety information – Draft guidelines issued

    The registration platform for cosmetic raw mate...
  • Technical guidelines for reporting cosmetics formulas

    Technical guidelines for reporting cosmetics formulas – draft issued

    Technical guidelines for reporting cosmetics fo...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP